BioStem Technologies (OTC: BSEM)
Michael Fortunato, CPA has a strong background in accounting and financial management. With experience in various industries such as technology, healthcare, and finance, Michael has held key roles such as Controller, Director, and Chief Financial Officer. Michael's expertise includes technical accounting, reporting, M&A due diligence, and stock-based compensation. Michael's career has taken him through roles at companies like Facebook, Yahoo, and the U.S. Securities and Exchange Commission, showcasing their diverse skill set and experience. With a BS in Accounting from Rutgers University, Michael Fortunato, CPA brings a wealth of knowledge to their current role as Chief Financial Officer at BioStem Technologies.
BioStem Technologies (OTC: BSEM)
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.